Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7Z624
UPID:
CMKMT_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z624; Q4ZG15; Q53SS6; Q8N6P5; Q9H5G8
Background:
Calmodulin-lysine N-methyltransferase, encoded by the gene with accession number Q7Z624, plays a crucial role in post-translational modifications by catalyzing the trimethylation of 'Lys-116' in calmodulin. This specific enzymatic activity is pivotal for the regulation of calcium signaling pathways, which are fundamental for cellular processes.
Therapeutic significance:
The protein is implicated in Hypotonia-cystinuria syndrome, a condition marked by generalized hypotonia, nephrolithiasis, and growth hormone deficiency. Understanding the role of Calmodulin-lysine N-methyltransferase could open doors to potential therapeutic strategies for this syndrome and related metabolic disorders.